The National Institute for Health and Care Excellence (NICE) has issued a second Appraisal Consultation Document (ACD) not recommending the routine National Health Service use of Venclexta (venetoclax) for patients with certain types of difficult-to-treat relapsed and refractory chronic lymphocytic leukemia (CLL).
There were 4 medical presentations: two given by
Dr Alison McCraig Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
as well as presentations by
Dr Emilio Cosimo Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
Dr Ailsa Holroyd Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University.
The presentations can be found here.
European Medical Agency - On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixathon, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Dr Claire Dearden gave two very interesting talks at the London meeting. Understanding CLL - Who and when to treat and How to treat in 2016 and beyond
Rupert Beazley a patient and trustee offers his experience of CLL and treatment. They can be found here.
CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.
Today’s Final Appraisal Determination (FAD) recommends that:
1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:
· who have had at least 1 prior therapy or
CLLSA is pleased to share that the Accelerated Access Review final report has now been published; it has been long awaited.
CLL Support Association is member of the Blood Cancer Alliance and supports the demand for the reinstatement of recently halted therapies by NHS England; in particular reinstatement of stem cell transplants for patients with a rare blood cancer Waldenstroms Macroglobulinaemia (WM)..
Yesterdays letter and the BCA demand
During 2016 CLLSA and patients have worked hard with other stakeholders to capture the patient and carer perspective and deliver this during the appraisal of Ibrutinib by The Scottish Medicines Consortium (SMC). Yesterday SMC announced that ibrutinib (Imbruvica) has been approved for restricted use by NHS Scotland to treat 17p TP53 CLL patients
We are very sorry to tell members that our friend and colleague Tricia Gardom died on Wednesday 8th June.
Tricia was a CLLSA member from 2006 and absolutely dedicated to fighting for people affected CLL and raising awareness of our plight. Even when so unwell over her last several months Tricia was there to help others in our on-line community